Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Avecia, Pfizer Enter Manufacturing Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Avecia, Pfizer Enter Manufacturing Pact

Avecia Biotechnology has entered an agreement with Pfizer for the commercial supply of a key component of Pfizer’s Macugen (pegaptanib sodium injection).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Avecia Biotechnology has entered an agreement with Pfizer for the commercial supply of a key component of Pfizer’s Macugen (pegaptanib sodium injection). Pfizer markets the drug in the E.U. for the treatment of wet Age-Related Macular Degeneration. The agreement includes technology transfer, process validation and commercial supply of a key component of Macugen.

“The agreement with Pfizer to manufacture a key component of this commercial oligonucleotide-based therapeutic is testament to our experience, reliability and quality standards with regard to technology transfer, process validation and the manufacture of oligonucleotide drug substances,” says Detlef Rethage, president of Avecia Biotechnology. Avecia was acquired by Merck in December 2009.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics